Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Malignant Melanoma

Free Subscription Articles published in Melanoma Res Retrieve available abstracts of 218 articles: HTML format Text format

Single Articles

December 2018
1. 
   A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma: Erratum.
   Melanoma Res. 2018;28:655.
   PubMed     Text format    
   
   
   November 2018
2. SALMI S, Siiskonen H, Sironen R, Tyynela-Korhonen K, et al
   The number and localization of CD68+ and CD163+ macrophages in different stages of cutaneous melanoma.
   Melanoma Res. 2018 Nov 5. doi: 10.1097/CMR.0000000000000522.
   PubMed     Text format     Abstract available
   
   
   
3. YANG N, Lu J, Lu Y, Guo J, et al
   Primary malignant melanotic melanoma and hypomelanotic melanoma of the female urethra: case series and a review of the literature in China.
   Melanoma Res. 2018 Nov 2. doi: 10.1097/CMR.0000000000000521.
   PubMed     Text format     Abstract available
   
   
   October 2018
4. PEPIN F, Julien AS, Fugaru I, Lihimdi N, et al
   Regression rate of choroidal melanoma following iodine-125 brachytherapy is not associated with metastatic spread.
   Melanoma Res. 2018 Oct 31. doi: 10.1097/CMR.0000000000000540.
   PubMed     Text format     Abstract available
   
   
   
5. ABBOTT JL, Qureshi MM, Truong MT, Sahni D, et al
   Comparing survival outcomes in early stage desmoplastic melanoma with or without adjuvant radiation.
   Melanoma Res. 2018 Oct 31. doi: 10.1097/CMR.0000000000000532.
   PubMed     Text format     Abstract available
   
   
   
6. ZHANG D, Wang Z, Shang D, Yu J, et al
   Incidence and prognosis of brain metastases in cutaneous melanoma patients: a population-based study.
   Melanoma Res. 2018 Oct 30. doi: 10.1097/CMR.0000000000000538.
   PubMed     Text format     Abstract available
   
   
   
7. DRAGO JZ, Lawrence D, Livingstone E, Zimmer L, et al
   Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study.
   Melanoma Res. 2018 Oct 29. doi: 10.1097/CMR.0000000000000527.
   PubMed     Text format     Abstract available
   
   
   
8. BUYUKKAPU BAY S, Kebudi R, Zulfikar B
   Cutaneous adverse event associated with vemurafenib in a 3-year-old pediatric patient with BRAF mutation-positive metastatic melanoma and factor X deficiency.
   Melanoma Res. 2018 Oct 29. doi: 10.1097/CMR.0000000000000537.
   PubMed     Text format     Abstract available
   
   
   
9. VUJIC I, Gandini S, Stanganelli I, Fierro MT, et al
   A meta-analysis of melanoma risk in industrial workers.
   Melanoma Res. 2018 Oct 26. doi: 10.1097/CMR.0000000000000531.
   PubMed     Text format     Abstract available
   
   
   
10. MARCOVAL J, Sabate-Llobera A, Bermejo J, Fornons-Servent R, et al
    Hibernoma as an incidental finding in the 18F-FDG PET/CT of a patient with melanoma.
    Melanoma Res. 2018 Oct 24. doi: 10.1097/CMR.0000000000000530.
    PubMed     Text format     Abstract available
    
    
    
11. ABDEL-RAHMAN O
    Population-based validation of the National Cancer Comprehensive Network recommendations for baseline imaging workup of cutaneous melanoma.
    Melanoma Res. 2018 Oct 22. doi: 10.1097/CMR.0000000000000528.
    PubMed     Text format     Abstract available
    
    
    
12. BELLOCQ D, Roy P, Kodjikian L, Mathis T, et al
    20-year assessment of metastatic latency and subsequent time to death after proton therapy for uveal melanomas.
    Melanoma Res. 2018 Oct 12. doi: 10.1097/CMR.0000000000000519.
    PubMed     Text format     Abstract available
    
    
    
13. VAN LAAR RK, Lincoln MT, van Laar BJ
    A plasma microRNA biomarker of melanoma as a personalised assessment of treatment response.
    Melanoma Res. 2018 Oct 12. doi: 10.1097/CMR.0000000000000492.
    PubMed     Text format     Abstract available
    
    
    
14. PETRELLI F, Ardito R, Merelli B, Lonati V, et al
    Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis.
    Melanoma Res. 2018 Oct 10. doi: 10.1097/CMR.0000000000000520.
    PubMed     Text format     Abstract available
    
    
    
15. DABROSIN N, Sloth Juul K, Baehr Georgsen J, Andrup S, et al
    Innate immune cell infiltration in melanoma metastases affects survival and is associated with BRAFV600E mutation status.
    Melanoma Res. 2018 Oct 5. doi: 10.1097/CMR.0000000000000515.
    PubMed     Text format     Abstract available
    
    
    
16. LASKE J, Meier F, Bauer A, Beissert S, et al
    Tattoo-associated complications of metastatic melanoma treated with dabrafenib and trametinib.
    Melanoma Res. 2018;28:485-487.
    PubMed     Text format    
    
    
    September 2018
17. HALFPENNY NJA, Scott DA, Thompson JC, Gurung B, et al
    A practical approach to predict expansion of evidence networks: a case study in treatment-naive advanced melanoma.
    Melanoma Res. 2018 Sep 29. doi: 10.1097/CMR.0000000000000513.
    PubMed     Text format     Abstract available
    
    
    
18. HWANG SJE, Park JJW, Wakade D, Chou S, et al
    Cutaneous adverse events of anti-programmed death 1 antibodies combined with anti-cytotoxic T-lymphocyte-associated protein 4 therapy use in patients with metastatic melanoma.
    Melanoma Res. 2018 Sep 29. doi: 10.1097/CMR.0000000000000518.
    PubMed     Text format     Abstract available
    
    
    
19. YIP RHL, Lee LH, Schaeffer DF, Horst BA, et al
    Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.
    Melanoma Res. 2018 Sep 25. doi: 10.1097/CMR.0000000000000502.
    PubMed     Text format     Abstract available
    
    
    
20. YIN G, Guo W, Chen X, Huang Z, et al
    Prognosis of endoscopic surgery and traditional open resection in mucosal melanoma of the nasal cavity and paranasal sinus.
    Melanoma Res. 2018 Sep 25. doi: 10.1097/CMR.0000000000000516.
    PubMed     Text format     Abstract available
    
    
    
21. GHATE S, Ionescu-Ittu R, Burne R, Ndife B, et al
    Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive.
    Melanoma Res. 2018 Sep 21. doi: 10.1097/CMR.0000000000000504.
    PubMed     Text format     Abstract available
    
    
    
22. SCAINI MC, Pigozzo J, Pizzi M, Manicone M, et al
    Clonal heterogeneity of melanoma in a paradigmatic case study: future prospects for circulating melanoma cells.
    Melanoma Res. 2018 Sep 14. doi: 10.1097/CMR.0000000000000510.
    PubMed     Text format     Abstract available
    
    
    
23. TINGFENG X, Fuqiang P, Dong L
    Expression and clinical significance of S100 family genes in patients with melanoma.
    Melanoma Res. 2018 Sep 13. doi: 10.1097/CMR.0000000000000512.
    PubMed     Text format     Abstract available
    
    
    
24. TARHINI A, Ghate SR, Ionescu-Ittu R, Manceur AM, et al
    Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma.
    Melanoma Res. 2018 Sep 13. doi: 10.1097/CMR.0000000000000507.
    PubMed     Text format     Abstract available
    
    
    
25. SHAH S, Luke JJ, Jacene HA, Chen T, et al
    Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma.
    Melanoma Res. 2018 Sep 11. doi: 10.1097/CMR.0000000000000509.
    PubMed     Text format     Abstract available
    
    
    
26. SEREMET T, Planken S, Schwarze JK, Jansen Y, et al
    Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitors refractory advanced melanoma.
    Melanoma Res. 2018 Sep 11. doi: 10.1097/CMR.0000000000000501.
    PubMed     Text format     Abstract available
    
    
    
27. CHRISTENSEN L, Scott J, Bordeaux J
    Use of gene expression profile testing as a prognostic tool in early-stage cutaneous melanoma - compelling but not ready for primetime.
    Melanoma Res. 2018 Sep 11. doi: 10.1097/CMR.0000000000000506.
    PubMed     Text format     Abstract available
    
    
    
28. DE MELO AC, Wainstein AJA, Buzaid AC, Thuler LCS, et al
    Melanoma signature in Brazil: epidemiology, incidence, mortality, and trend lessons from a continental mixed population country in the past 15 years.
    Melanoma Res. 2018 Sep 10. doi: 10.1097/CMR.0000000000000511.
    PubMed     Text format     Abstract available
    
    
    
29. ZHAO B, Cheng X, Zhou X
    The BET-bromodomain inhibitor JQ1 mitigates vemurafenib drug resistance in melanoma.
    Melanoma Res. 2018 Sep 5. doi: 10.1097/CMR.0000000000000497.
    PubMed     Text format     Abstract available
    
    
    
30. TROMME I, Sacre L, Hammouch F, Richez P, et al
    Melanoma diagnosis: predictive value of macroscopic changes observed by the patient.
    Melanoma Res. 2018 Sep 5. doi: 10.1097/CMR.0000000000000496.
    PubMed     Text format     Abstract available
    
    
    
31. NYE A, Collins JD, Porter CL, Montes de Oca M, et al
    Predictive genetic profiles for regional lymph node metastasis in primary cutaneous melanoma: a case-matched pilot study.
    Melanoma Res. 2018 Sep 1. doi: 10.1097/CMR.0000000000000499.
    PubMed     Text format     Abstract available
    
    
    August 2018
32. KANG R, Lipner S
    Assessment of internet sources on subungual melanoma.
    Melanoma Res. 2018 Aug 30. doi: 10.1097/CMR.0000000000000508.
    PubMed     Text format     Abstract available
    
    
    
33. TAN SY, Najita J, Li X, Strazzulla LC, et al
    Clinicopathologic features correlated with paradoxical outcomes in stage IIC versus IIIA melanoma patients.
    Melanoma Res. 2018 Aug 30. doi: 10.1097/CMR.0000000000000483.
    PubMed     Text format     Abstract available
    
    
    
34. DIAMANTOPOULOS PT, Stoungioti S, Anastasopoulou A, Papaxoinis G, et al
    Incomplete Vogt-Koyanagi-Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma.
    Melanoma Res. 2018 Aug 30. doi: 10.1097/CMR.0000000000000505.
    PubMed     Text format     Abstract available
    
    
    
35. SWORDS DS, Andtbacka RHI, Bowles TL, Hyngstrom JR, et al
    Routine retrieval of pelvic sentinel lymph nodes for melanoma rarely adds prognostic information or alters management.
    Melanoma Res. 2018 Aug 29. doi: 10.1097/CMR.0000000000000498.
    PubMed     Text format     Abstract available
    
    
    
36. KENESSEY I, Kramer Z, Istvan L, Cserepes MT, et al
    Inhibition of epidermal growth factor receptor improves antitumor efficacy of vemurafenib in BRAF-mutant human melanoma in preclinical model.
    Melanoma Res. 2018 Aug 17. doi: 10.1097/CMR.0000000000000488.
    PubMed     Text format     Abstract available
    
    
    
37. HERBERT A, Koo MM, Barclay ME, Greenberg DC, et al
    Stage-specific incidence trends of melanoma in an English region, 1996-2015: longitudinal analyses of population-based data.
    Melanoma Res. 2018 Aug 13. doi: 10.1097/CMR.0000000000000489.
    PubMed     Text format     Abstract available
    
    
    
38. YAN J, Wu X, Yu J, Ma M, et al
    Establishment and characterization of melanoma patient-derived xenograft models for preclinical evaluation of novel therapeutics.
    Melanoma Res. 2018 Aug 6. doi: 10.1097/CMR.0000000000000494.
    PubMed     Text format     Abstract available
    
    
    
39. GROGAN N, Swami U, Bossler AD, Zakharia Y, et al
    Toxicities with targeted therapies after immunotherapy in metastatic melanoma.
    Melanoma Res. 2018 Aug 6. doi: 10.1097/CMR.0000000000000493.
    PubMed     Text format     Abstract available
    
    
    
40. LIU G, Wang Y, Fei F, Wang X, et al
    Clinical characteristics and preliminary morphological observation of 47 cases of primary anorectal malignant melanomas.
    Melanoma Res. 2018 Aug 3. doi: 10.1097/CMR.0000000000000491.
    PubMed     Text format     Abstract available
    
    
    
41. MONTAUDIE H, Picard A, Panaia-Ferrari P, Boukari F, et al
    Painful acute thyroiditis following a first cure of Ipilimumab plus Nivolumab for metastatic melanoma.
    Melanoma Res. 2018;28:368-369.
    PubMed     Text format    
    
    
    July 2018
42. NICHOLAS MN, Khoja L, Atenafu EG, Hogg D, et al
    Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: The Princess Margaret Cancer Centre experience.
    Melanoma Res. 2018 Jul 31. doi: 10.1097/CMR.0000000000000468.
    PubMed     Text format     Abstract available
    
    
    
43. SUN H, Chen Y, Chen Y, Liu D, et al
    Primary malignant melanoma of the cervix: 14 cases and literature overview.
    Melanoma Res. 2018 Jul 23. doi: 10.1097/CMR.0000000000000469.
    PubMed     Text format     Abstract available
    
    
    
44. AYDOGMUS-OZTURK F, Gunaydin K, Ozturk M, Jahan H, et al
    Effect of Sideritis leptoclada against HT-144 human malignant melanoma.
    Melanoma Res. 2018 Jul 19. doi: 10.1097/CMR.0000000000000487.
    PubMed     Text format     Abstract available
    
    
    
45. SAGLAM O, Naqvi SMH, Zhang Y, Mesa T, et al
    Female genitourinary tract melanoma: mutation analysis with clinicopathologic correlation: a single-institution experience.
    Melanoma Res. 2018 Jul 19. doi: 10.1097/CMR.0000000000000480.
    PubMed     Text format     Abstract available
    
    
    
46. NUNES LF, Quintella Mendes GL, Koifman RJ
    Acral melanoma: a retrospective cohort from the Brazilian National Cancer Institute (INCA).
    Melanoma Res. 2018 Jul 16. doi: 10.1097/CMR.0000000000000476.
    PubMed     Text format     Abstract available
    
    
    
47. OLAVERRIA SALAVAGGIONE GN, Duggan MC, Carson WE
    Analysis of MLN4924 (pevonedistat) as a potential therapeutic agent in malignant melanoma.
    Melanoma Res. 2018 Jul 16. doi: 10.1097/CMR.0000000000000474.
    PubMed     Text format     Abstract available
    
    
    
48. BRUNSSEN A, Jansen L, Eisemann N, Waldmann A, et al
    Long-term relative survival from melanoma in Germany 1997-2013.
    Melanoma Res. 2018 Jul 16. doi: 10.1097/CMR.0000000000000482.
    PubMed     Text format     Abstract available
    
    
    
49. HUTCHINSON PE, Halsall JA, Popovici S, Papadogeorgakis E, et al
    Compromised vitamin D receptor signalling in malignant melanoma is associated with tumour progression and mitogen-activated protein kinase activity.
    Melanoma Res. 2018 Jul 12. doi: 10.1097/CMR.0000000000000475.
    PubMed     Text format     Abstract available
    
    
    
50. FERRIS LK, Gerami P, Skelsey MK, Peck G, et al
    Real-world performance and utility of a noninvasive gene expression assay to evaluate melanoma risk in pigmented lesions.
    Melanoma Res. 2018 Jul 12. doi: 10.1097/CMR.0000000000000478.
    PubMed     Text format     Abstract available
    
    
    
51. LYTH J
    Conditional recurrence-free survival in patients with primary stage I-II cutaneous malignant melanoma - a population-based study.
    Melanoma Res. 2018 Jul 9. doi: 10.1097/CMR.0000000000000479.
    PubMed     Text format     Abstract available
    
    
    
52. LAMIAUX M, Scalbert C, Lepesant P, Desmedt E, et al
    Severe skin toxicity with organ damage under the combination of targeted therapy following immunotherapy in metastatic melanoma.
    Melanoma Res. 2018 Jul 6. doi: 10.1097/CMR.0000000000000472.
    PubMed     Text format     Abstract available
    
    
    
53. GORLOV I, Orlow I, Ringelberg C, Hernando E, et al
    Identification of gene expression levels in primary melanoma associated with clinically meaningful characteristics.
    Melanoma Res. 2018 Jul 2. doi: 10.1097/CMR.0000000000000473.
    PubMed     Text format     Abstract available
    
    
    
54. GOMEZ-LEON N, Pacheco-Barcia V, Ballesteros AI, Fraga J, et al
    Skeletal muscle and solitary bone metastases from malignant melanoma: multimodality imaging and oncological outcome.
    Melanoma Res. 2018 Jul 2. doi: 10.1097/CMR.0000000000000466.
    PubMed     Text format     Abstract available
    
    
    June 2018
55. URBONAS V, Smailyte G
    Combination of cytokine-directed and anti-programmed cell death protein 1 therapy - a new attractive option in melanoma treatment?
    Melanoma Res. 2018 Jun 29. doi: 10.1097/CMR.0000000000000470.
    PubMed     Text format     Abstract available
    
    
    
56. RAMBHIA PH, Honda K, Arbesman J
    Nivolumab induced inflammation of seborrheic keratoses: a novel cutaneous manifestation in a metastatic melanoma patient.
    Melanoma Res. 2018 Jun 29. doi: 10.1097/CMR.0000000000000477.
    PubMed     Text format     Abstract available
    
    
    
57. MENSHAWY A, Eltonob AA, Barkat SA, Ghanem A, et al
    Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials.
    Melanoma Res. 2018 Jun 27. doi: 10.1097/CMR.0000000000000467.
    PubMed     Text format     Abstract available
    
    
    
58. PUZA CJ, Barbas AS, Mosca PJ
    Outcomes of patients with a pretransplant history of early-stage melanoma.
    Melanoma Res. 2018 Jun 25. doi: 10.1097/CMR.0000000000000471.
    PubMed     Text format     Abstract available
    
    
    
59. MORGADO-CARRASCO D, Moreno-Rivera N, Fusta-Novell X, Garcia-Herrera A, et al
    Histiocytoid Sweet's syndrome during combined therapy with BRAF and MEK inhibitors for metastatic melanoma.
    Melanoma Res. 2018;28:256-257.
    PubMed     Text format    
    
    
    May 2018
60. HAFLIGER EM, Ramelyte E, Mangana J, Kunz M, et al
    Metastatic acral lentiginous melanoma in a tertiary referral center in Switzerland: a systematic analysis.
    Melanoma Res. 2018 May 29. doi: 10.1097/CMR.0000000000000465.
    PubMed     Text format     Abstract available
    
    
    
61. IACONO D, Cinausero M, Gerratana L, Angione V, et al
    Tumour-infiltrating lymphocytes, programmed death ligand 1 and cyclooxygenase-2 expression in skin melanoma of elderly patients: clinicopathological correlations.
    Melanoma Res. 2018 May 22. doi: 10.1097/CMR.0000000000000462.
    PubMed     Text format     Abstract available
    
    
    
62. BRUTTING J, Bergmann M, Garzarolli M, Rauschenberg R, et al
    Unmet information needs of patients with melanoma in Germany.
    Melanoma Res. 2018 May 21. doi: 10.1097/CMR.0000000000000464.
    PubMed     Text format     Abstract available
    
    
    
63. TETERYCZ P, Jagodzinska-Mucha P, Cybulska-Stopa B, Mariuk-Jarema A, et al
    High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors.
    Melanoma Res. 2018 May 18. doi: 10.1097/CMR.0000000000000461.
    PubMed     Text format     Abstract available
    
    
    
64. FACINA AS, Facina G, Guerreiro da Silva IDC, Correa SAA, et al
    Pregnancy and the apoptotic pathway in experimental melanoma.
    Melanoma Res. 2018 May 17. doi: 10.1097/CMR.0000000000000452.
    PubMed     Text format     Abstract available
    
    
    
65. ZHOU X, Zeng Y, Jiang H, Xia L, et al
    Predictive value of excision repair cross-complementing group 2 gene Lys751Gln and Asp312Asn polymorphisms in melanoma risk.
    Melanoma Res. 2018 May 15. doi: 10.1097/CMR.0000000000000463.
    PubMed     Text format     Abstract available
    
    
    
66. TSOUTSOS D, Papadopoulos S, Kehagias G, Mara A, et al
    Epidemiological trends in the diagnosis of melanoma in a Southern European population: analysis of a large database from a tertiary referral center.
    Melanoma Res. 2018 May 14. doi: 10.1097/CMR.0000000000000456.
    PubMed     Text format     Abstract available
    
    
    
67. AFZAL MZ, Shirai K
    Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center.
    Melanoma Res. 2018 May 10. doi: 10.1097/CMR.0000000000000459.
    PubMed     Text format     Abstract available
    
    
    
68. TENGDA L, Shuping L, Mingli G, Jie G, et al
    Serum exosomal microRNAs as potent circulating biomarkers for melanoma.
    Melanoma Res. 2018 May 10. doi: 10.1097/CMR.0000000000000450.
    PubMed     Text format     Abstract available
    
    
    
69. ASCIERTO PA, Bastholt L, Ferrucci PF, Hansson J, et al
    The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study.
    Melanoma Res. 2018 May 10. doi: 10.1097/CMR.0000000000000455.
    PubMed     Text format     Abstract available
    
    
    
70. MOSHE M, Levi A, Ad-El D, Ben-Amitai D, et al
    Malignant melanoma clinically mimicking pyogenic granuloma: comparison of clinical evaluation and histopathology.
    Melanoma Res. 2018 May 10. doi: 10.1097/CMR.0000000000000451.
    PubMed     Text format     Abstract available
    
    
    
71. SCHOUWENBURG MG, Jochems A, Leeneman B, Franken MG, et al
    Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes.
    Melanoma Res. 2018 May 10. doi: 10.1097/CMR.0000000000000453.
    PubMed     Text format     Abstract available
    
    
    
72. GONG HZ, Zheng HY, Li J
    The clinical significance of KIT mutations in melanoma: a meta-analysis.
    Melanoma Res. 2018 May 9. doi: 10.1097/CMR.0000000000000454.
    PubMed     Text format     Abstract available
    
    
    April 2018
73. SEBESTYEN T, Mohos A, Liszkay G, Somlai B, et al
    Correlation with lymphocyte infiltration, but lack of prognostic significance of MECA-79-positive high endothelial venules in primary malignant melanoma.
    Melanoma Res. 2018 Apr 20. doi: 10.1097/CMR.0000000000000457.
    PubMed     Text format     Abstract available
    
    
    
74. LEE WJ, Lee YJ, Shin HJ, Won CH, et al
    Clinicopathological significance of tumor-infiltrating lymphocytes and programmed death-1 expression in cutaneous melanoma: a comparative study on clinical subtypes.
    Melanoma Res. 2018 Apr 9. doi: 10.1097/CMR.0000000000000449.
    PubMed     Text format     Abstract available
    
    
    
75. SIA DIT, Thaung C, O'Hanlon-Brown C, Cohen VML, et al
    Immune privilege: failure of immunotherapy in controlling metastatic cutaneous melanoma to the eye.
    Melanoma Res. 2018 Apr 9. doi: 10.1097/CMR.0000000000000443.
    PubMed     Text format     Abstract available
    
    
    
76. BASSOLI S, Pellegrini C, Longo C, Di Nardo L, et al
    Clinical, dermoscopic, and confocal features of nevi and melanomas in a multiple primary melanoma patient with the MITF p.E318K homozygous mutation.
    Melanoma Res. 2018;28:166-169.
    PubMed     Text format    
    
    
    
77. TAKAHASHI A, Tsutsumida A, Namikawa K, Yamazaki N, et al
    Fulminant type 1 diabetes associated with nivolumab in a patient with metastatic melanoma.
    Melanoma Res. 2018;28:159-160.
    PubMed     Text format    
    
    
    March 2018
78. TURNER KA, Manouchehri JM, Kalafatis M
    Sensitization of recombinant human tumor necrosis factor-related apoptosis-inducing ligand-resistant malignant melanomas by quercetin.
    Melanoma Res. 2018 Mar 28. doi: 10.1097/CMR.0000000000000447.
    PubMed     Text format     Abstract available
    
    
    
79. TERNOV NK, Lambine TL, Wagenblast ALH, Clasen-Linde E, et al
    Targeted ultrasound and fine-needle aspiration cytology for sentinel node diagnostics in early-stage melanoma: a validation study.
    Melanoma Res. 2018 Mar 27. doi: 10.1097/CMR.0000000000000448.
    PubMed     Text format     Abstract available
    
    
    
80. CHESNEY J, Imbert-Fernandez Y, Telang S, Baum M, et al
    Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors.
    Melanoma Res. 2018 Mar 21. doi: 10.1097/CMR.0000000000000444.
    PubMed     Text format     Abstract available
    
    
    
81. KLEEMANN J, Hrgovic I, Ter-Nedden J, Kleimann P, et al
    Fatty acid receptor GPR120: a novel marker for human melanoma.
    Melanoma Res. 2018 Mar 21. doi: 10.1097/CMR.0000000000000445.
    PubMed     Text format     Abstract available
    
    
    
82. LADE-KELLER J, Yuusufi S, Riber-Hansen R, Steiniche T, et al
    Telomerase reverse transcriptase promoter mutations and solar elastosis in cutaneous melanoma.
    Melanoma Res. 2018 Mar 21. doi: 10.1097/CMR.0000000000000446.
    PubMed     Text format     Abstract available
    
    
    
83. NASARRE P, Bonilla IV, Metcalf JS, Hilliard EG, et al
    TRAF3-interacting protein 3, a new oncotarget, promotes tumor growth in melanoma.
    Melanoma Res. 2018 Mar 16. doi: 10.1097/CMR.0000000000000440.
    PubMed     Text format     Abstract available
    
    
    
84. GESKIN LJ, Damiano JJ, Patrone CC, Butterfield LH, et al
    Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma.
    Melanoma Res. 2018 Mar 14. doi: 10.1097/CMR.0000000000000441.
    PubMed     Text format     Abstract available
    
    
    
85. DE UNAMUNO B, Garcia-Casado Z, Banuls J, Requena C, et al
    CDKN2A germline alterations in melanoma patients with personal or familial history of pancreatic cancer.
    Melanoma Res. 2018 Mar 14. doi: 10.1097/CMR.0000000000000442.
    PubMed     Text format     Abstract available
    
    
    
86. STOWMAN AM, Hickman AW, Mauldin IS, Mahmutovic A, et al
    Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures.
    Melanoma Res. 2018 Mar 13. doi: 10.1097/CMR.0000000000000439.
    PubMed     Text format     Abstract available
    
    
    
87. FOLEY KC, Nishimura MI, Moore TV
    Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma.
    Melanoma Res. 2018 Mar 8. doi: 10.1097/CMR.0000000000000436.
    PubMed     Text format     Abstract available
    
    
    February 2018
88. MACHIRAJU D, Moll I, Gebhardt C, Sucker A, et al
    STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon-alpha.
    Melanoma Res. 2018 Feb 26. doi: 10.1097/CMR.0000000000000435.
    PubMed     Text format     Abstract available
    
    
    
89. DIMITRIOU F, Frauchiger AL, Urosevic-Maiwald M, Naegeli MC, et al
    Sarcoid-like reactions in patients receiving modern melanoma treatment.
    Melanoma Res. 2018 Feb 26. doi: 10.1097/CMR.0000000000000437.
    PubMed     Text format     Abstract available
    
    
    
90. GONZALEZ-CAO M, Mayo de Las Casas C, Jordana Ariza N, Manzano JL, et al
    Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy.
    Melanoma Res. 2018 Feb 23. doi: 10.1097/CMR.0000000000000432.
    PubMed     Text format     Abstract available
    
    
    
91. TESTORI AA, Suciu S, van Akkooi ACJ, Suppa M, et al
    Lymph node ratio as a prognostic factor in melanoma: results from European Organization for Research and Treatment of Cancer 18871, 18952, and 18991 studies.
    Melanoma Res. 2018 Feb 9. doi: 10.1097/CMR.0000000000000433.
    PubMed     Text format     Abstract available
    
    
    
92. GANZETTI G, Sartini D, Campanati A, Rubini C, et al
    Nicotinamide N-methyltransferase: potential involvement in cutaneous malignant melanoma.
    Melanoma Res. 2018 Feb 7. doi: 10.1097/CMR.0000000000000430.
    PubMed     Text format     Abstract available
    
    
    
93. YANAGITA M, Luke JJ, Hodi FS, Janne PA, et al
    Isolation and characterization of circulating melanoma cells by size filtration and fluorescent in-situ hybridization.
    Melanoma Res. 2018 Feb 5. doi: 10.1097/CMR.0000000000000431.
    PubMed     Text format     Abstract available
    
    
    
94. KOTHAPALLI A, Khattak MA
    Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series.
    Melanoma Res. 2018 Feb 5. doi: 10.1097/CMR.0000000000000434.
    PubMed     Text format     Abstract available
    
    
    
95. EISENSTEIN A, Panova IP, Chung HJ, Goldberg LJ, et al
    Quantitative assessment of neuropilin-2 as a simple and sensitive diagnostic assay for spitzoid melanocytic lesions.
    Melanoma Res. 2018;28:71-75.
    PubMed     Text format     Abstract available
    
    
    
96. ISAKOVIC AM, Petricevic SM, Ristic SM, Popadic DM, et al
    In vitro and in vivo antimelanoma effect of ethyl ester cyclohexyl analog of ethylenediamine dipropanoic acid.
    Melanoma Res. 2018;28:8-20.
    PubMed     Text format     Abstract available
    
    
    January 2018
97. GEUKES FOPPEN MH, Boogerd W, Blank CU, van Thienen JV, et al
    Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.
    Melanoma Res. 2018 Jan 19. doi: 10.1097/CMR.0000000000000429.
    PubMed     Text format     Abstract available
    
    
    
98. NARDIN C, Mateus C, Texier M, Lanoy E, et al
    Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases.
    Melanoma Res. 2018 Jan 19. doi: 10.1097/CMR.0000000000000413.
    PubMed     Text format     Abstract available
    
    
    
99. ROSE AM, Radia UK, Luo R, Kalirai H, et al
    Multiple primary malignancies and prolonged survival in a patient with widespread metastatic cutaneous melanoma.
    Melanoma Res. 2018 Jan 17. doi: 10.1097/CMR.0000000000000426.
    PubMed     Text format    
    
    
    
100. ZHU W, Li S, Zou B, Liu H, et al
     Expressions and clinical significance of HER4 and CD44 in sinonasal mucosal malignant melanoma.
     Melanoma Res. 2018 Jan 5. doi: 10.1097/CMR.0000000000000428.
     PubMed     Text format     Abstract available
     
     
     
101. DANISH H, Ferris MJ, Balagamwala E, Switchenko JM, et al
     Comparative outcomes and toxicities for ruthenium-106 versus palladium-103 in the treatment of choroidal melanoma.
     Melanoma Res. 2018 Jan 3. doi: 10.1097/CMR.0000000000000420.
     PubMed     Text format     Abstract available
     
     
     December 2017
102. DEL CARPIO HUERTA LP, Mas Castells M, Anguera Palacios G, Sullivan I, et al
     A novel KRAS mutation in metastasic conjunctival melanoma: a case report and literature review.
     Melanoma Res. 2017 Dec 20. doi: 10.1097/CMR.0000000000000423.
     PubMed     Text format     Abstract available
     
     
     
103. WEITMAN ES, Perez M, Thompson JF, Andtbacka RHI, et al
     Quality of life patient-reported outcomes for locally advanced cutaneous melanoma.
     Melanoma Res. 2017 Dec 19. doi: 10.1097/CMR.0000000000000425.
     PubMed     Text format     Abstract available
     
     
     
104. GALLO S, Coha V, Caravelli D, Becco P, et al
     BRAF-inhibitors can exert control of disease in BRAF T599I mutated melanoma: a case report.
     Melanoma Res. 2017 Dec 11. doi: 10.1097/CMR.0000000000000417.
     PubMed     Text format     Abstract available
     
     
     
105. BISSCHOP C, Ter Elst A, Bosman LJ, Platteel I, et al
     Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform.
     Melanoma Res. 2017 Dec 11. doi: 10.1097/CMR.0000000000000421.
     PubMed     Text format     Abstract available
     
     
     
106. SEREMET T, Planken S, Schreuer M, Jansen Y, et al
     Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.
     Melanoma Res. 2017 Dec 8. doi: 10.1097/CMR.0000000000000415.
     PubMed     Text format     Abstract available
     
     
     
107. LOYSON T, Werbrouck E, Punie K, Bonne L, et al
     Hemorrhage of liver and bone metastases as a result of rapid response to dual BRAF/MEK inhibition in metastatic melanoma: a case report.
     Melanoma Res. 2017 Dec 5. doi: 10.1097/CMR.0000000000000419.
     PubMed     Text format     Abstract available
     
     
     
108. MENZIES S, Barry R, Ormond P
     Multiple primary melanoma: a single centre retrospective review.
     Melanoma Res. 2017;27:638-640.
     PubMed     Text format     Abstract available
     
     
     
109. SCHINZARI G, Rossi E, Cassano A, Dadduzio V, et al
     Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study.
     Melanoma Res. 2017;27:591-595.
     PubMed     Text format     Abstract available
     
     
     
110. HALLMEYER S, Gonzalez R, Lawson DH, Cranmer LD, et al
     Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.
     Melanoma Res. 2017;27:585-590.
     PubMed     Text format     Abstract available
     
     
     
111. ROBINSON JP, Rebecca VW, Kircher DA, Silvis MR, et al
     Resistance mechanisms to genetic suppression of mutant NRAS in melanoma.
     Melanoma Res. 2017;27:545-557.
     PubMed     Text format     Abstract available
     
     
     
112. VAN DER WEYDEN L, Arends MJ, Brenn T, Tuting T, et al
     Widespread spontaneous hyperproliferation, melanosis and melanoma in Hgf-Cdk4R24C mice.
     Melanoma Res. 2017 Dec 1. doi: 10.1097/CMR.0000000000000414.
     PubMed     Text format    
     
     
     November 2017
113. BRANCA M, Orso S, Molinari RC, Xu H, et al
     Is nonmetastatic cutaneous melanoma predictable through genomic biomarkers?
     Melanoma Res. 2017 Nov 29. doi: 10.1097/CMR.0000000000000412.
     PubMed     Text format     Abstract available
     
     
     
114. CHESNEY J, Awasthi S, Curti B, Hutchins L, et al
     Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma.
     Melanoma Res. 2017 Nov 22. doi: 10.1097/CMR.0000000000000399.
     PubMed     Text format     Abstract available
     
     
     
115. HADDEN NJ, McIntosh JRD, Jay S, Whittaker PJ, et al
     Prognostic factors in patients with metastatic spinal cord compression secondary to melanoma: a systematic review.
     Melanoma Res. 2017 Nov 14. doi: 10.1097/CMR.0000000000000411.
     PubMed     Text format     Abstract available
     
     
     
116. KUO JC, Lilly LB, Hogg D
     Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma: a case report and literature review.
     Melanoma Res. 2017 Nov 14. doi: 10.1097/CMR.0000000000000410.
     PubMed     Text format     Abstract available
     
     
     
117. BRZOZOWSKA M, Wierzba W, Sliwczynski A, Swierkowski M, et al
     Analysis of survival of patients treated with vemurafenib, ipilimumab and dabrafenib for advanced skin melanoma in daily clinical practice (Real-World Data): retrospective analysis of patients treated under drug/reimbursement programmes in Poland in 2
     Melanoma Res. 2017 Nov 8. doi: 10.1097/CMR.0000000000000408.
     PubMed     Text format     Abstract available
     
     
     October 2017
118. PACHMANN K, Willecke-Hochmuth R, Schneider K, Kaatz M, et al
     Circulating epithelial tumor cells as a prognostic tool for malignant melanoma.
     Melanoma Res. 2017 Oct 25. doi: 10.1097/CMR.0000000000000407.
     PubMed     Text format     Abstract available
     
     
     
119. TANG Y, Xie C, Zhang Y, Qin Y, et al
     Overexpression of mRNA-decapping enzyme 1a predicts disease-specific survival in malignant melanoma.
     Melanoma Res. 2017 Oct 25. doi: 10.1097/CMR.0000000000000406.
     PubMed     Text format     Abstract available
     
     
     
120. UPRETY D, Bista A, Chennamadhavuni A, Niroula A, et al
     Survival trends among patients with metastatic melanoma in the pretargeted and the post-targeted era: a US population-based study.
     Melanoma Res. 2017 Oct 11. doi: 10.1097/CMR.0000000000000394.
     PubMed     Text format     Abstract available
     
     
     
121. FAILING JJ, Yan Y, Porrata LF, Markovic SN, et al
     Lymphocyte-to-monocyte ratio is associated with survival in pembrolizumab-treated metastatic melanoma patients.
     Melanoma Res. 2017 Oct 9. doi: 10.1097/CMR.0000000000000404.
     PubMed     Text format     Abstract available
     
     
     
122. SHEN X, Fan Y, Cao S
     A review of primary malignant melanoma arising in an ovarian cystic teratoma.
     Melanoma Res. 2017 Oct 9. doi: 10.1097/CMR.0000000000000402.
     PubMed     Text format     Abstract available
     
     
     
123. ALESSI C, Scapulatempo Neto C, Viana CR, Vazquez VL, et al
     PD-1/PD-L1 and VEGF-A/VEGF-C expression in lymph node microenvironment and association with melanoma metastasis and survival.
     Melanoma Res. 2017 Oct 3. doi: 10.1097/CMR.0000000000000396.
     PubMed     Text format     Abstract available
     
     
     
124. TSIOGKA A, Jansky GL, Bauer JW, Koelblinger P, et al
     Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma.
     Melanoma Res. 2017;27:524-525.
     PubMed     Text format    
     
     
     
125. ABOUDARAM A, Modesto A, Chaltiel L, Gomez-Roca C, et al
     Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination.
     Melanoma Res. 2017;27:485-491.
     PubMed     Text format     Abstract available
     
     
     September 2017
126. MARTINEZ-GARCIA MA, Riveiro-Falkenbach E, Rodriguez-Peralto JL, Nagore E, et al
     A prospective multicenter cohort study of cutaneous melanoma: clinical staging and potential associations with HIF-1alpha and VEGF expressions.
     Melanoma Res. 2017 Sep 6. doi: 10.1097/CMR.0000000000000393.
     PubMed     Text format     Abstract available
     
     
     
127. DE SOUZA NETO FP, Bernardes SS, Marinello PC, Melo GP, et al
     Metformin: oxidative and proliferative parameters in-vitro and in-vivo models of murine melanoma.
     Melanoma Res. 2017 Sep 4. doi: 10.1097/CMR.0000000000000391.
     PubMed     Text format     Abstract available
     
     
     
128. YUKI A, Takenouchi T, Takatsuka S, Ishiguro T, et al
     A case of pure red cell aplasia during nivolumab therapy for cardiac metastatic melanoma.
     Melanoma Res. 2017 Sep 1. doi: 10.1097/CMR.0000000000000392.
     PubMed     Text format     Abstract available
     
     
     
129. TAHA T, Tzuk-Shina T, Forschner I, Bar-Sela G, et al
     Acute motor and sensory axonal neuropathy related to treatment with MEK inhibitors in a patient with advanced melanoma.
     Melanoma Res. 2017 Sep 1. doi: 10.1097/CMR.0000000000000390.
     PubMed     Text format     Abstract available
     
     
     August 2017
130. LI Y, Umbach DM, Li L
     Putative genomic characteristics of BRAF V600K versus V600E cutaneous melanoma.
     Melanoma Res. 2017 Aug 28. doi: 10.1097/CMR.0000000000000388.
     PubMed     Text format     Abstract available
     
     
     
131. TARHINI AA, Floros T, Lin HM, Lin Y, et al
     A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma.
     Melanoma Res. 2017 Aug 18. doi: 10.1097/CMR.0000000000000383.
     PubMed     Text format     Abstract available
     
     
     
132. GLITZA IC, Guha-Thakurta N, D'Souza NM, Amaria RN, et al
     Bevacizumab as an effective treatment for radiation necrosis after radiotherapy for melanoma brain metastases.
     Melanoma Res. 2017 Aug 16. doi: 10.1097/CMR.0000000000000389.
     PubMed     Text format     Abstract available
     
     
     
133. PURI A, Homsi J
     The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis.
     Melanoma Res. 2017 Aug 16. doi: 10.1097/CMR.0000000000000387.
     PubMed     Text format     Abstract available
     
     
     
134. BARBARIC J, Laversanne M, Znaor A
     Malignant melanoma incidence trends in a Mediterranean population following socioeconomic transition and war: results of age-period-cohort analysis in Croatia, 1989-2013.
     Melanoma Res. 2017 Aug 10. doi: 10.1097/CMR.0000000000000385.
     PubMed     Text format     Abstract available
     
     
     
135. GARDNER LJ, Ward M, Andtbacka RHI, Boucher KM, et al
     Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis.
     Melanoma Res. 2017 Aug 10. doi: 10.1097/CMR.0000000000000382.
     PubMed     Text format     Abstract available
     
     
     
136. ROGIERS A, Borght SV, Tuand K, Wolter P, et al
     Response to targeted therapy in two patients with metastatic melanoma carrying rare BRAF exon 15 mutations: A598_T599insV and V600_K601delinsE.
     Melanoma Res. 2017 Aug 10. doi: 10.1097/CMR.0000000000000376.
     PubMed     Text format     Abstract available
     
     
     
137. GOGAS HJ, Karalexi MA, Dessypris N, Antoniadis AG, et al
     The role of depression and personality traits in patients with melanoma: a South-European study.
     Melanoma Res. 2017 Aug 10. doi: 10.1097/CMR.0000000000000380.
     PubMed     Text format     Abstract available
     
     
     
138. GLADFELTER P, Darwish NHE, Mousa SA
     Current status and future direction in the management of malignant melanoma.
     Melanoma Res. 2017 Aug 10. doi: 10.1097/CMR.0000000000000379.
     PubMed     Text format     Abstract available
     
     
     
139. GRANGE F, Mohr P, Harries M, Ehness R, et al
     Economic burden of advanced melanoma in France, Germany and the UK: a retrospective observational study (Melanoma Burden-of-Illness Study).
     Melanoma Res. 2017 Aug 10. doi: 10.1097/CMR.0000000000000372.
     PubMed     Text format     Abstract available
     
     
     
140. STOWMAN AM, Hickman AW, Gru AA, Slingluff CL Jr, et al
     Histopathologic review of negative sentinel lymph node biopsies in thin melanomas: an argument for the routine use of immunohistochemistry.
     Melanoma Res. 2017;27:369-376.
     PubMed     Text format     Abstract available
     
     
     
141. DE ROSA F, Ridolfi L, Fiammenghi L, Petrini M, et al
     Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience.
     Melanoma Res. 2017;27:351-357.
     PubMed     Text format     Abstract available
     
     
     
142. SANGALLI A, Orlandi E, Poli A, Maurichi A, et al
     Sex-specific effect of RNASEL rs486907 and miR-146a rs2910164 polymorphisms' interaction as a susceptibility factor for melanoma skin cancer.
     Melanoma Res. 2017;27:309-314.
     PubMed     Text format     Abstract available
     
     
     July 2017
143. SOSSAU D, Kofler L, Eigentler T
     Type 1 diabetes mellitus caused by treatment with low-dose interferon-alpha in a melanoma patient.
     Melanoma Res. 2017 Jul 19. doi: 10.1097/CMR.0000000000000381.
     PubMed     Text format     Abstract available
     
     
     
144. BORGHI A, Corazza M, Virgili A, Lambertini AG, et al
     Impact of socioeconomic status and district of residence on cutaneous malignant melanoma prognosis: a survival study on incident cases between 1991 and 2011 in the province of Ferrara, northern Italy.
     Melanoma Res. 2017 Jul 18. doi: 10.1097/CMR.0000000000000378.
     PubMed     Text format     Abstract available
     
     
     
145. GRATZ V, Luttmann N, Haase O, Langan EA, et al
     Meningeal melanomatosis following discontinuation of dabrafenib: implications for the maintenance of long-term complete remission.
     Melanoma Res. 2017 Jul 18. doi: 10.1097/CMR.0000000000000373.
     PubMed     Text format     Abstract available
     
     
     
146. GAUCI ML, Laly P, Sarah LL, Behin A, et al
     Focal necrotizing myopathy with 'dropped-head syndrome' induced by cobimetinib in metastatic melanoma.
     Melanoma Res. 2017 Jul 7. doi: 10.1097/CMR.0000000000000377.
     PubMed     Text format     Abstract available
     
     
     June 2017
147. WANDLER A, Riber-Hansen R, Hager H, Hamilton-Dutoit SJ, et al
     Quantification of microRNA-21 and microRNA-125b in melanoma tissue.
     Melanoma Res. 2017 Jun 13. doi: 10.1097/CMR.0000000000000374.
     PubMed     Text format     Abstract available
     
     
     
148. TOMIZUKA T, Namikawa K, Higashi T
     Characteristics of melanoma in Japan: a nationwide registry analysis 2011-2013.
     Melanoma Res. 2017 Jun 12. doi: 10.1097/CMR.0000000000000375.
     PubMed     Text format     Abstract available
     
     
     
149. SOARES CD, Borges CF, Sena-Filho M, Almeida OP, et al
     Prognostic significance of cyclooxygenase 2 and phosphorylated Akt1 overexpression in primary nonmetastatic and metastatic cutaneous melanomas.
     Melanoma Res. 2017 Jun 9. doi: 10.1097/CMR.0000000000000368.
     PubMed     Text format     Abstract available
     
     
     
150. DAVICK JJ, Wick MR, Gru AA
     Development of a biclonal cutaneous T-cell lymphoproliferative process during treatment with immune checkpoint inhibitors for metastatic melanoma.
     Melanoma Res. 2017 Jun 1. doi: 10.1097/CMR.0000000000000371.
     PubMed     Text format     Abstract available
     
     
     
151. GIUDICE G, Robusto F, Vestita M, Annoscia P, et al
     Single-stage excision and sentinel lymph node biopsy in cutaneous melanoma in selected patients: a retrospective case-control study.
     Melanoma Res. 2017 Jun 1. doi: 10.1097/CMR.0000000000000370.
     PubMed     Text format     Abstract available
     
     
     
152. WANG Y, Wen XZ, Ba HJ, Li DD, et al
     A prognostic model for resectable acral melanoma patients on the basis of preoperative inflammatory markers.
     Melanoma Res. 2017 Jun 1. doi: 10.1097/CMR.0000000000000365.
     PubMed     Text format     Abstract available
     
     
     
153. MIRZA S, Hill E, Ludlow SP, Nanjappa S, et al
     Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome.
     Melanoma Res. 2017;27:271-273.
     PubMed     Text format     Abstract available
     
     
     
154. HAUEIS SA, Kranzlin P, Mangana J, Cheng PF, et al
     Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching?
     Melanoma Res. 2017;27:231-237.
     PubMed     Text format     Abstract available
     
     
     May 2017
155. FURDOVA A, Sramka M, Chorvath M, Kralik G, et al
     Clinical experience of stereotactic radiosurgery at a linear accelerator for intraocular melanoma.
     Melanoma Res. 2017 May 17. doi: 10.1097/CMR.0000000000000364.
     PubMed     Text format     Abstract available
     
     
     
156. MANGANA J, Cheng PF, Kaufmann C, Amann VC, et al
     Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland.
     Melanoma Res. 2017 May 15. doi: 10.1097/CMR.0000000000000359.
     PubMed     Text format     Abstract available
     
     
     
157. GUADAGNI S, Fiorentini G, Clementi M, Palumbo G, et al
     MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study.
     Melanoma Res. 2017 May 10. doi: 10.1097/CMR.0000000000000367.
     PubMed     Text format     Abstract available
     
     
     
158. LAKHTER AJ, Naidu SR
     Cyclic AMP-Epac signaling pathway contributes to repression of PUMA transcription in melanoma cells.
     Melanoma Res. 2017 May 4. doi: 10.1097/CMR.0000000000000363.
     PubMed     Text format     Abstract available
     
     
     
159. HOLTKAMP LHJ, Read RL, Emmett L, Thompson JF, et al
     Futility of imaging to stage melanoma patients with a positive sentinel lymph node.
     Melanoma Res. 2017 May 4. doi: 10.1097/CMR.0000000000000362.
     PubMed     Text format     Abstract available
     
     
     
160. STABLER S, Becquart C, Dumezy F, Terriou L, et al
     Hemophagocytic lymphohistiocytosis in patients with metastatic malignant melanoma.
     Melanoma Res. 2017 May 3. doi: 10.1097/CMR.0000000000000354.
     PubMed     Text format     Abstract available
     
     
     April 2017
161. MENDT M, Cardier JE
     Activation of the CXCR4 chemokine receptor enhances biological functions associated with B16 melanoma liver metastasis.
     Melanoma Res. 2017 Apr 25. doi: 10.1097/CMR.0000000000000346.
     PubMed     Text format     Abstract available
     
     
     
162. KYRGIDIS A, Lallas A, Moscarella E, Longo C, et al
     Does pregnancy influence melanoma prognosis? A meta-analysis.
     Melanoma Res. 2017 Apr 20. doi: 10.1097/CMR.0000000000000334.
     PubMed     Text format     Abstract available
     
     
     
163. DIAMANTOPOULOS PT, Gaggadi M, Kassi E, Benopoulou O, et al
     Late-onset nivolumab-mediated pneumonitis in a patient with melanoma and multiple immune-related adverse events.
     Melanoma Res. 2017 Apr 17. doi: 10.1097/CMR.0000000000000355.
     PubMed     Text format     Abstract available
     
     
     
164. PISCIOLI F, Pusiol T, Roncati L
     Critical points of T1 stage in primary melanoma.
     Melanoma Res. 2017 Apr 13. doi: 10.1097/CMR.0000000000000357.
     PubMed     Text format    
     
     
     
165. MURER C, Kranzlin-Stieger P, French LE, Dummer R, et al
     Successful treatment with imatinib after nilotinib and ipilimumab in a c-kit-mutated advanced melanoma patient: a case report.
     Melanoma Res. 2017 Apr 13. doi: 10.1097/CMR.0000000000000358.
     PubMed     Text format     Abstract available
     
     
     
166. TARHINI AA, Moschos SJ, Lin Y, Lin HM, et al
     Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-alpha2b in patients with metastatic melanoma.
     Melanoma Res. 2017 Apr 7. doi: 10.1097/CMR.0000000000000353.
     PubMed     Text format     Abstract available
     
     
     
167. THOMSON CH, Cassell O, Peach H, Holloway S, et al
     Neuropathic pain and quality of life after wide local excision and sentinel lymph node biopsy for melanoma: a multicentre study.
     Melanoma Res. 2017;27:121-125.
     PubMed     Text format     Abstract available
     
     
     
168. ROGIERS A, Wolter P, Bechter O
     Dabrafenib plus trametinib rechallenge in four melanoma patients who previously progressed on this combination.
     Melanoma Res. 2017;27:164-167.
     PubMed     Text format     Abstract available
     
     
     
169. BLACKMON JT, Dhawan R, Terry NL, Conry RM, et al
     Response of BRAF inhibitor-associated squamous cell lung carcinoma to drug withdrawal.
     Melanoma Res. 2017;27:159-163.
     PubMed     Text format     Abstract available
     
     
     
170. AMODE R, Baroudjian B, Kowal A, Jebali M, et al
     Anti-programmed cell death protein 1 tolerance and efficacy after ipilimumab immunotherapy: observational study of 39 patients.
     Melanoma Res. 2017;27:110-115.
     PubMed     Text format     Abstract available
     
     
     March 2017
171. DE GIORGI V, Grazzini M, Benemei S, Marchionni N, et al
     beta-Blocker use and reduced disease progression in patients with thick melanoma: 8 years of follow-up.
     Melanoma Res. 2017 Mar 24. doi: 10.1097/CMR.0000000000000317.
     PubMed     Text format     Abstract available
     
     
     
172. HINTZSCHE JD, Gorden NT, Amato CM, Kim J, et al
     Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.
     Melanoma Res. 2017 Mar 14. doi: 10.1097/CMR.0000000000000345.
     PubMed     Text format     Abstract available
     
     
     
173. LEON-FERRE RA, Kottschade LA, Block MS, McWilliams RR, et al
     Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma.
     Melanoma Res. 2017 Mar 14. doi: 10.1097/CMR.0000000000000344.
     PubMed     Text format     Abstract available
     
     
     
174. CARRERA C, Gual A, Diaz A, Puig-Butille JA, et al
     Prognostic role of the histological subtype of melanoma on the hands and feet in Caucasians.
     Melanoma Res. 2017 Mar 14. doi: 10.1097/CMR.0000000000000340.
     PubMed     Text format     Abstract available
     
     
     
175. FALLENI M, Savi F, Tosi D, Agape E, et al
     M1 and M2 macrophages' clinicopathological significance in cutaneous melanoma.
     Melanoma Res. 2017 Mar 7. doi: 10.1097/CMR.0000000000000352.
     PubMed     Text format     Abstract available
     
     
     
176. FUKUDA K, Funakoshi T, Sakurai T, Nakamura Y, et al
     Peptide-pulsed dendritic cell vaccine in combination with carboplatin and paclitaxel chemotherapy for stage IV melanoma.
     Melanoma Res. 2017 Mar 3. doi: 10.1097/CMR.0000000000000342.
     PubMed     Text format     Abstract available
     
     
     
177. BLASIG H, Bender C, Hassel JC, Eigentler TK, et al
     Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanoma.
     Melanoma Res. 2017 Mar 2. doi: 10.1097/CMR.0000000000000341.
     PubMed     Text format     Abstract available
     
     
     
178. DE GIORGI V, Gori A, Savarese I, D'Errico A, et al
     Clinical and dermoscopic features of truly amelanotic plantar melanoma.
     Melanoma Res. 2017 Mar 1. doi: 10.1097/CMR.0000000000000337.
     PubMed     Text format     Abstract available
     
     
     
179. LOQUAI C, Schmidtmann I, Garzarolli M, Kaatz M, et al
     Interactions from complementary and alternative medicine in patients with melanoma.
     Melanoma Res. 2017 Mar 1. doi: 10.1097/CMR.0000000000000339.
     PubMed     Text format     Abstract available
     
     
     February 2017
180. DESVIGNES C, Abirached H, Templier C, Drumez E, et al
     BRAF inhibitor discontinuation and rechallenge in advanced melanoma patients with a complete initial treatment response.
     Melanoma Res. 2017 Feb 24. doi: 10.1097/CMR.0000000000000350.
     PubMed     Text format     Abstract available
     
     
     
181. TAS F, Erturk K
     Scalp melanoma is associated with high mitotic rate and is a poor prognostic factor for recurrence and outcome.
     Melanoma Res. 2017 Feb 23. doi: 10.1097/CMR.0000000000000351.
     PubMed     Text format     Abstract available
     
     
     
182. VIZKELETI L, Kiss T, Koroknai V, Ecsedi S, et al
     Altered integrin expression patterns shown by microarray in human cutaneous melanoma.
     Melanoma Res. 2017 Feb 23. doi: 10.1097/CMR.0000000000000322.
     PubMed     Text format     Abstract available
     
     
     
183. ITCHINS M, Ascierto PA, Menzies AM, Oatley M, et al
     A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy.
     Melanoma Res. 2017 Feb 22. doi: 10.1097/CMR.0000000000000343.
     PubMed     Text format     Abstract available
     
     
     
184. MADU MF, Timmerman P, Wouters MW, van der Hiel B, et al
     PET/CT surveillance detects asymptomatic recurrences in stage IIIB and IIIC melanoma patients: a prospective cohort study.
     Melanoma Res. 2017 Feb 20. doi: 10.1097/CMR.0000000000000347.
     PubMed     Text format     Abstract available
     
     
     
185. LI FJ, Li LM, Zhang RH, Xu C, et al
     The role of 5-hydroxymethylcytosine in melanoma.
     Melanoma Res. 2017 Feb 20. doi: 10.1097/CMR.0000000000000349.
     PubMed     Text format     Abstract available
     
     
     
186. TESIO V, Ribero S, Castelli L, Bassino S, et al
     Psychological characteristics of early-stage melanoma patients: a cross-sectional study on 204 patients.
     Melanoma Res. 2017 Feb 15. doi: 10.1097/CMR.0000000000000348.
     PubMed     Text format     Abstract available
     
     
     
187. RIBERO S, Longo C, Specchio F, Piana S, et al
     Lymph nodes' capsular naevi are associated with high naevus count in melanoma patients: a case-control study.
     Melanoma Res. 2017 Feb 1. doi: 10.1097/CMR.0000000000000328.
     PubMed     Text format     Abstract available
     
     
     January 2017
188. PELLEGRINI C, Maturo MG, Martorelli C, Suppa M, et al
     Characterization of melanoma susceptibility genes in high-risk patients from Central Italy.
     Melanoma Res. 2017 Jan 31. doi: 10.1097/CMR.0000000000000323.
     PubMed     Text format     Abstract available
     
     
     
189. LINO-SILVA LS, Salcedo-Hernandez RA, Garcia-Perez L, Meneses-Garcia A, et al
     Basal neutrophil-to-lymphocyte ratio is associated with overall survival in melanoma.
     Melanoma Res. 2017 Jan 25. doi: 10.1097/CMR.0000000000000333.
     PubMed     Text format     Abstract available
     
     
     
190. GRAY A, Grushchak S, Mudaliar K, Kliethermes S, et al
     The microenvironment in primary cutaneous melanoma with associated spontaneous tumor regression: evaluation for T-regulatory cells and the presence of an immunosuppressive microenvironment.
     Melanoma Res. 2017 Jan 25. doi: 10.1097/CMR.0000000000000331.
     PubMed     Text format     Abstract available
     
     
     
191. OBEID JM, Hu Y, Erdag G, Leick KM, et al
     The heterogeneity of tumor-infiltrating CD8+ T cells in metastatic melanoma distorts their quantification: how to manage heterogeneity?
     Melanoma Res. 2017 Jan 21. doi: 10.1097/CMR.0000000000000330.
     PubMed     Text format     Abstract available
     
     
     
192. OBA J, Esmaeli B, Ellerhorst JA, Lyons GR, et al
     Trends in hepatocyte growth factor, insulin-like growth factor 1, thyroid-stimulating hormone, and leptin expression levels in uveal melanoma patient serum and tumor tissues: correlation to disease progression.
     Melanoma Res. 2017 Jan 21. doi: 10.1097/CMR.0000000000000329.
     PubMed     Text format     Abstract available
     
     
     
193. LADWA R, Atkinson V
     The cessation of anti-PD-1 antibodies of complete responders in metastatic melanoma.
     Melanoma Res. 2017 Jan 17. doi: 10.1097/CMR.0000000000000336.
     PubMed     Text format     Abstract available
     
     
     
194. TAS F, Erturk K
     Recurrence behavior in early-stage cutaneous melanoma: pattern, timing, survival, and influencing factors.
     Melanoma Res. 2017 Jan 17. doi: 10.1097/CMR.0000000000000332.
     PubMed     Text format     Abstract available
     
     
     
195. DE HAAN J, Lok CA, de Groot CJ, Crijns MB, et al
     Melanoma during pregnancy: a report of 60 pregnancies complicated by melanoma.
     Melanoma Res. 2017 Jan 17. doi: 10.1097/CMR.0000000000000327.
     PubMed     Text format     Abstract available
     
     
     
196. LV C, Dai H, Sun M, Zhao H, et al
     Mesenchymal stem cells induce epithelial mesenchymal transition in melanoma by paracrine secretion of transforming growth factor-beta.
     Melanoma Res. 2017 Jan 5. doi: 10.1097/CMR.0000000000000325.
     PubMed     Text format     Abstract available
     
     
     
197. BORRONI RG, Manganoni AM, Grassi S, Grasso M, et al
     Genetic counselling and high-penetrance susceptibility gene analysis reveal the novel CDKN2A p.D84V (c.251A>T) mutation in melanoma-prone families from Italy.
     Melanoma Res. 2017 Jan 4. doi: 10.1097/CMR.0000000000000324.
     PubMed     Text format     Abstract available
     
     
     December 2016
198. LINO-SILVA LS, Castillo-Medina AL, Salcedo-Hernandez RA, Garcia-Perez L, et al
     Exhaustive pathologic work-up in sentinel lymph node biopsy for melanoma: is it necessary?
     Melanoma Res. 2016 Dec 27. doi: 10.1097/CMR.0000000000000319.
     PubMed     Text format     Abstract available
     
     
     
199. MICEVIC G, Theodosakis N, Taube JM, Bosenberg MW, et al
     Attenuation of genome-wide 5-methylcytosine level is an epigenetic feature of cutaneous malignant melanomas.
     Melanoma Res. 2016 Dec 16. doi: 10.1097/CMR.0000000000000315.
     PubMed     Text format     Abstract available
     
     
     
200. BEHLING J, Kaes J, Munzel T, Grabbe S, et al
     New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
201. MININI R, Rohrmann S, Braun R, Korol D, et al
     Incidence trends and clinical-pathological characteristics of invasive cutaneous melanoma from 1980 to 2010 in the canton of Zurich, Switzerland.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
202. PISCIOLI F, Pusiol T, Roncati L
     Thin melanoma subtyping fits well with the American Joint Committee on Cancer staging system.
     Melanoma Res. 2016;26:636.
     PubMed     Text format    
     
     
     
203. PISCIOLI F, Pusiol T, Roncati L
     Histopathological determination of thin melanomas at risk for metastasis.
     Melanoma Res. 2016;26:635.
     PubMed     Text format    
     
     
     November 2016
204. LEONTOVICH AA, Dronca RS, Nevala WK, Thompson MA, et al
     Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     October 2016
205. PAOLINO G, Panetta C, Cota C, Didona D, et al
     Vitamin D receptor immunohistochemistry variability in sun-exposed and non-sun-exposed melanomas.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
206. SHOUSHTARI AN, Bluth MJ, Goldman DA, Bitas C, et al
     Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
207. NGUYEN BH, Kuo J, Budiman A, Christie H, et al
     Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
208. VARTANIAN A, Baryshnikova M, Burova O, Afanasyeva D, et al
     Inhibitor of vasculogenic mimicry restores sensitivity of resistant melanoma cells to DNA-damaging agents.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
209. CHAKRAVARTI N, Ivan D, Trinh VA, Glitza IC, et al
     High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
210. LIM MS, Wang JH, Power DG, Redmond HP, et al
     Inflammatory regulation of stem-like cells in melanoma.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
211. ADAMS G, Foote M, Brown S, Burmeister B, et al
     Adjuvant external beam radiotherapy after therapeutic groin lymphadenectomy for patients with melanoma: a dosimetric comparison of three-dimensional conformal and intensity-modulated radiotherapy techniques.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
212. BOTTLAENDER L, Perier-Muzet M, Lapras V, Thomas L, et al
     Tumor-free osteosclerotic lesions in patients treated for metastatic melanoma using BRAF inhibitors.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
213. AMBER KT, Panganiban CM, Korta D, Feraudy S, et al
     A case report of bullous pemphigoid associated with a melanoma and review of the literature.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
214. MATHESON JA, Te Marvelde L, Mailer S, Speakman D, et al
     Prospective evaluation of prognostic indicators for early recurrence of cutaneous melanoma.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     September 2016
215. KUBECEK O, Kopecky J
     Microsatellite instability in melanoma: a comprehensive review.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     
216. MIRJACIC MARTINOVIC KM, Babovic NL, Dzodic RR, Jurisic VB, et al
     Beneficial in-vitro effects of interleukin-2, interleukin-12, and their combination on functional and receptor characteristics of natural killer cells in metastatic melanoma patients with normal serum lactate dehydrogenase levels.
     Melanoma Res. 2016.
     PubMed     Text format     Abstract available
     
     
     April 2016
217. CHENG C, Yang HW, Shang JF, Li WW, et al
     Identification of a small molecule that downregulates MITF expression and mediates antimelanoma activity in vitro.
     Melanoma Res. 2016;26:117-24.
     PubMed     Text format     Abstract available
     
     
     
218. WANG LE, Li C, Xiong P, Gershenwald JE, et al
     4-nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma: a case-control analysis.
     Melanoma Res. 2016;26:181-7.
     PubMed     Text format     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: